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Introduction: A growing number of studies have highlighted the potential of stem cell and more-differentiated
neural cell transplantation as intriguing therapeutic approaches for neural repair after spinal cord injury (SCI).
Methods: A conditionally immortalized neural stem cell line derived from human fetal spinal cord tissue (SPC-01)
was used to treat a balloon-induced SCI. SPC-01 cells were implanted into the lesion 1 week after SCI. To determine
the feasibility of tracking transplanted stem cells, a portion of the SPC-01 cells was labeled with poly-L-lysine-coated
superparamagnetic iron-oxide nanoparticles, and the animals grafted with labeled cells underwent magnetic
resonance imaging. Functional recovery was evaluated by using the BBB and plantar tests, and lesion morphology,
endogenous axonal sprouting and graft survival, and differentiation were analyzed. Quantitative polymerase chain
reaction (qPCR) was used to evaluate the effect of transplanted SPC-01 cells on endogenous regenerative
processes.
Results: Transplanted animals displayed significant motor and sensory improvement 2 months after SCI, when the
cells robustly survived in the lesion and partially filled the lesion cavity. qPCR revealed the increased expression of
rat and human neurotrophin and motor neuron genes. The grafted cells were immunohistologically positive for
glial fibrillary acidic protein (GFAP); however, we found 25% of the cells to be positive for Nkx6.1, an early motor
neuron marker. Spared white matter and the robust sprouting of growth-associated protein 43 (GAP43)+ axons
were found in the host tissue. Four months after SCI, the grafted cells matured into Islet2+ and choline
acetyltransferase (ChAT)+ neurons, and the graft was grown through with endogenous neurons. Grafted cells
labeled with poly-L-lysine-coated superparamagnetic nanoparticles before transplantation were detected in the
lesion on T2-weighted images as hypointense spots that correlated with histologic staining for iron and the human
mitochondrial marker MTCO2.
Conclusions: The transplantation of SPC-01 cells produced significant early functional improvement after SCI,
suggesting an early neurotrophic action associated with long-term restoration of the host tissue, making the cells a
promising candidate for future cell therapy in patients with SCI.
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Spinal cord injury (SCI) remains a very complex medical
and psychological challenge, both for patients and their
relatives and for the involved physicians. The unprece-
dented success of SCI research in the past few years has
resulted in significant advances [1,2]; nevertheless, clin-
ical treatment is still limited to the reduction of pain
and swelling and the prevention of secondary injury by
the administration of antiinflammatory drugs. Pathologic
changes after SCI are complex and include the interrup-
tion of ascending and descending pathways, the loss of
neurons and glial cells, inflammation, scar formation,
and demyelination [3,4]. These events suggest a number
of different steps required for SCI repair, such as minim-
izing progressive cell death and blocking scar formation;
replacing lost cells and stimulating the injured cord to
produce new cells; reconnecting injured nerve fibers
with their original targets or with substitute targets; and
maximizing the function of the spared nerve fibers by
repairing their myelin sheaths. Because of their spe-
cific properties, stem cells may eventually play a role
in many or all of these processes. Therefore, cell-
transplantation therapies have become a major focus
in preclinical research as a promising strategy for the
treatment of SCI [5].
Among the many different types of stem cells available
today, neural stem and progenitor cells (NSCs) are par-
ticularly useful tools for transplantation therapy, because
they have the ability to provide an unlimited source of
neurons, oligodendrocytes, and astrocytes for the treat-
ment of neurologic and/or neurodegenerative disorders
via cell replacement [6]. NSCs can be isolated from the
developing or adult central nervous system and can be
safely expanded in chemically defined culture media for
an extended period. They have immunomodulatory
properties [7] and also are able to produce a number of
growth factors that have strong neurotrophic and
neuroregenerative effects [8]. In addition, NSCs are
more kindred to nervous tissue in comparison to other
stem cell types (for example, mesenchymal stem cells
[9-11] and olfactory ensheathing cells [12]). A positive
effect of transplanted NSCs on functional outcome after
SCI was shown in several experiments using animal
models [13-16]. Moreover, from a clinical perspective, it
is important that implanted human NSCs have been
shown to give rise to mature neurons and oligodendro-
cytes and that they have promoted functional recovery
not only in SCI models in small animals, but also in in-
jured dogs [17].
The current study addresses a previously unexplored
issue in stem cell transplantation research for spinal
cord repair in what are, to our knowledge, the first SCI
experiments using a conditionally immortalized line of
human fetal neural stem cells derived from the spinalcord (SPC-01). For establishing this line, c-mycERTAM
technology was used in which a fusion protein compris-
ing a growth-promoting gene, c-myc, and a hormone re-
ceptor that is regulated by a synthetic drug, 4-hydroxy
-tamoxifen (4-OHT), were used to achieve conditional
growth control. Because of these manipulations, the im-
mortalizing gene is downregulated on transplantation
into the host spinal cord [18]. First, we report that SPC-
01 cells survive, engraft, differentiate and communicate
with the host environment after traumatic SCI in rats.
Second, we demonstrated that transplanted SPC-01 cells
survive in the lesion site while being tracked by in vivo
MRI by using poly-L-lysine-coated superparamagnetic
iron-oxide nanoparticles. Third, we showed that the
transplantation of SPC-01 cells into the lesioned rat
spinal cord improves functional outcome by partially
bridging the spinal cord lesion and providing trophic
support to the spared axons in the injured tissue.
Methods
Human fetal neural stem cells SPC-01
The human spinal cord cell line (SPC-01) was gener-
ated from 10-week-old human fetal spinal cord. Fetal tis-
sue was obtained from Advanced Bioscience Resources
(Alameda, CA, USA) after normal terminations and in
accordance with nationally (UK and/or USA) approved
ethical and legal guidelines [19,20]. Cells were prepared
by mechanical and enzymatic dissociation of the fetal
spinal cord cervical region into a single-cell suspension.
Subsequently, cells were conditionally immortalized with
the c-mycERTAM construct. This construct generates a c-
myc protein fused to a mutated estrogen receptor and is
transcriptionally active only in the presence of the syn-
thetic ligand 4-hydroxy tamoxifen. The method used is
the same as that published in Pollock et al. [18]. For
easier in vivo detection, the SPC-01 cells were trans-
duced with green fluorescent protein (GFP). The GFP-
expressing SPC-01 cells were generated by using a
lentiviral vector containing a ubiquitous chromatin open-
ing element (UCOE) to prevent silencing on engraftment,
as previously described [21]. Transduced SPC-01_GFP+
cells were frozen, stored in liquid nitrogen, and used
throughout the whole study.
SPC-01-GFP+ cells were routinely cultured in tissue-
culture flasks freshly coated with laminin (Sigma,
St. Louis, MO, USA; 20 μg/ml in DMEM:F12) for 1
hour at 37°C. Growth media comprising DMEM:F12
supplemented with HSA (0.03%) (Baxter Healthcare
Ltd., Norfolk, UK); L-glutamine (2 mM), human transfer-
rin (100 μg/ml), putrescine dihydrochloride (16.2 μg/ml),
human insulin (5 μg/ml), progesterone (60 ng/ml), sodium
selenite (selenium) (40 ng/ml), EGF (20 ng/ml), and
4-hydroxy-tamoxifen (4-OHT) (100 nM) all from Sigma;
FGF (10 ng/ml) (PeproTech, London, UK) was changed 3
Amemori et al. Stem Cell Research & Therapy 2013, 4:68 Page 3 of 15
http://stemcellres.com/content/4/3/68times per week. When 70% to 90% confluent, the
cells were passaged by using 0.25% TrypZean (Lonza,
Basel, Switzerland) for 2 minutes at 37°C followed by 0.25
mg/ml soybean trypsin inhibitor. SPC-01-GFP+ cells from
passages 26 through 29 were used in all experiments.
For magnetic labeling, the cells were incubated in a
culture medium containing 15.4 μg/ml of iron in the
form of poly-L-lysine-coated superparamagnetic-iron
-oxide (PLL-SPIO) nanoparticles for 72 hours before
transplantation [22]. The nanoparticles were washed out
by using HBSS (Invitrogen, Paisley, Scotland, UK), and
then the cells were harvested as described earlier.Animals
Ten-week-old male Wistar rats were obtained, and their
body weight ranged between 270 g and 300 g to
minimize differences in body size to achieve standard-
ized spinal cord lesions. To complete this study, 83 ani-
mals were used. The numbers of animals used for all
parts of the study are summarized in Additional file 1:
Table S1. All experiments were performed in accordance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) regarding the use of ani-
mals in research and were approved by the Ethics Com-
mittee of the Institute of Experimental Medicine ASCR,
Prague, Czech Republic.Spinal cord injury
A balloon-compression lesion was performed in a total
of 79 male Wistar rats, as described by Urdzikova
et al. [11]. In brief, the animals were anesthetized
with 2% isoflurane (Forane; Abbott Laboratories,
Queenborough, UK) and shaved on the back from C7
to Th1. Under sterile conditions, the skin was cut in
the midline from Th7 to Th12. The soft tissue was re-
moved, as well as the spinous processes of vertebrae
Th8 to Th11. A 2F Fogarty catheter was inserted into
the epidural space and advanced cranially for 1 cm, so
that the center of the balloon rested at the Th8 to
Th9 level of the spinal cord. The balloon was rapidly
inflated with 15 μl of saline for 5 minutes. The cath-
eter was then deflated and removed. The soft tissue
and skin were sutured with unresorbable thread, and
the animals were allowed to feed and drink ad libitum.
During the surgical procedure, the body temperature
of the animal was maintained at 37°C with a heating
pad, and 3% uurane in air was administered at a
flow rate of 0.3 L/min. After being returned to their
cages, the rats were assisted in feeding and urination
until they had recovered sufficiently to perform these
functions on their own. The animals received genta-
micin sulfate (5 mg/kg) for 3 days to prevent post-
operative infections.Transplantation
The animals were transplanted 1 week after SCI. This
time point is generally accepted as a suitable therapeutic
window, as the inflammatory reaction (creating a hostile
environment for cell-transplant survival) decreases dur-
ing the first 7 days, and the glial scar that prevents graft-
host tissue communication is not yet developed [23].
The animals were secured in a stereotaxic apparatus
with a rat-specific vertebra holder (Cunningham spinal
adaptor; Stoelting Co., Wood Dale, IL, USA). The spinal
cord was exposed at T8. In total, 5 × 105 SPC-01 cells/5
μl (either unlabeled or labeled with nanoparticles) were
injected through a glass pipette into the center of the le-
sion at a depth of 1 mm below the dorsal surface at a
rate of 1 μl/min by using a Nano-Injector (Stoelting).
Cells were harvested as described earlier, and the cell
suspension was prepared just before the transplantation
procedure. The number of cells was determined based
on the results obtained from our pilot study, in which
1 × 105 SPC-01 cells/1 μl were also injected into the
proximal, central, and distal parts of the lesioned spinal
cord. However, the survival rate of the transplanted
cells was worse than when injecting 5 × 105 SPC-01
cells/5 μl into the lesion. The glass pipette was kept in
place after injection for a further 5 minutes to prevent
leakage of the cell suspension. The control group re-
ceived 5 μl of saline. Triple-drug immunosuppression
was used to prevent graft rejection [24]. Cyclosporine
A (10 mg/kg), azathioprine sodium (2 mg/kg), methyl-
prednisolone (2 mg/kg, tapered to 0.5 mg/kg), and
ampicillin (50 to 100 mg/kg) were administered 1 day
before transplantation and throughout the experiment
(for 2 months or 4 months).
MRI
To visualize the grafted cells in vivo, part of the cells were
labeled with poly-L-lysine-coated superparamagnetic iron-
oxide (PLL-SPIO) nanoparticles, and four animals grafted
with labeled cells, and four animals injected with saline
underwent magnetic resonance imaging (MRI). MR im-
ages were taken 5 days after SCI (that is, before transplant-
ation), and 1, 4, and 8 weeks after transplantation (that is,
2, 5, and 9 weeks after SCI). In total, 5 × 105 SPC-01 cells
labeled with PLL-SPIO nanoparticles were injected in the
same way as described earlier.
MR images were obtained with a 4.7-T spectrometer
(Bruker BioSpin, Ettlingen, Germany) by using a home-
made surface coil incorporated in an animal holder dedi-
cated for spinal cord measurements. The rats were
anesthetized by 1.5% to 2% isoflurane in air. The respir-
ation of the animals was monitored during the MR mea-
surements. The rats were examined on their backs. After
initial pilot scans, which were used for proper geometry
setting, a turbo-spin echo sequence was used for the
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quence parameters were turbo factor, 16; repetition time,
TR = 2,000 ms; effective echo time, TE = 69.9 msec;
number of acquisitions, AC = 48; field of view, FOV =
5 × 3 cm; matrix size, MTX = 256 × 256; slice thickness,
0.75 mm.
Functional analysis
For motor testing, hindlimb locomotor activity after SCI
was assessed with the Basso, Beattie, and Bresnahan
(BBB) test [25] (SCI and SPC-01, n = 20; SCI only, n =
16). The rats were placed on a floor within a circular en-
closure. Their hindlimb joint movement, paw placement,
weight support, forelimb-hindlimb coordination, and so
on, were evaluated by using a 0 to 21-point scale.
For sensitivity testing, hindpaw-withdrawal latency to
noxious thermal stimuli was assessed with a Plantar Test
apparatus (Ugo Basile, Comerio, Italy) (the same animals
that underwent BBB testing). The animals were placed
in a clear plastic chamber and acclimated for 10 minutes
until becoming quiescent. The hindpaw received a heat
stimulus through a glass plate. The withdrawal latencies
were measured 5 times for each hindpaw at 5-minute
intervals.
The motor function of the hindlimbs was also exam-
ined with the walking-beam test (SCI and SPC-01,
n = 8; SCI only, n = 8). The apparatus consisted of a
3.4-cm-wide and 140-cm-long wooden rectangular
beam. A goal box was placed at one end. The central 1
m of the beam was used to evaluate the walking dis-
tance. The latency and the trajectory to traverse the
beam were recorded with a video-tracking system
(TSE-Systems Inc., Bad Homburg, Germany) for a
maximum of 60 seconds. After pretraining, two trials
were given each day for 3 consecutive days. The animals
were examined before surgery and every week from the
second week after the injection of SPC-01 cells or saline.
A 0 to 7-point scale modified from Goldstein [26] was
used to evaluate the locomotor function.
The average of five values was used for statistical
evaluation. The data are expressed as mean ± SEM.
All data were compared between the sham-operated
group and the transplanted group by a two-sample
t test for independent samples, if the two samples
had equal variances. If they had unequal variances,
the Mann–Whitney test was used for evaluation. A
P value <0.05 was considered statistically significant.
All behavioral tests were performed by two independ-
ent blind observers.
Histologic and immunohistochemical analysis
To analyze the volume of the spared white and gray
matter and the extent of axonal sprouting, animals with
SCI only (n = 8) and animals grafted with SPC-01 cells(n = 7) were killed 8 weeks after transplantation by
transcardial perfusion. For perfusion, the animals were
deeply anesthetized with ketamine (100 mg/kg) and
xylazine (20 mg/kg). Their chests were opened, and
transcardial perfusion was performed with phosphate
buffer until the liver tissue was clean, followed by perfu-
sion with a 4% paraformaldehyde (PFA) solution in
phosphate buffer. A 2-cm-long segment of the spinal
cord was dissected between 1 cm cranial and 1 cm cau-
dal to the injury epicenter. Serial cross sections, 5 μm
thick, were cut by using a K400 microtome (Microm
GmbH, Walldorf Germany) after paraffin embedding,
and were stained with either Luxol-fast blue (1 g of
Luxol-fast blue dissolved in 100 ml of 96% ethanol with
5 ml of 10% acetic acid) or cresyl violet (0.25 g of cresyl
violet dissolved in 100 ml of distilled water with 1 ml of
10% acetic acid) to distinguish the white and gray matter
or by an anti-GAP43 antibody (Millipore, Billerica, MA,
USA; MAB347) to evaluate axonal sprouting. For
volumetric measurements, six sections were selected
at 1-mm intervals along the rostrocaudal axis, and
whole images of the spinal cord were taken with an
Axioskop 2 plus microscope (Carl Zeiss AG, Oberkochen,
Germany) and analyzed with ImageJ software (Wayne
Rasband, National Institutes of Health, USA) [11]. Axonal
sprouting was expressed as the mean number of GAP43-
positive fibers per section [27]. High-magnification images
of transverse sections, separated by a 1-mm distance in
all animal groups stained for GAP43, were taken, and
GAP43-positive fibers were manually counted. Each
counted fiber was marked with red color to avoid
double counting.
For immunohistochemical evaluation of the grafts, ani-
mals grafted with SPC-01 cells were killed 8 (n = 14) or
17 weeks (n = 5) after transplantation by transcardial
perfusion. To monitor the survival, migration, and differ-
entiation of the transplanted cells, serial longitudinal
sections of the spinal cord (14 μm) were cut through the
areas of interest, by using a Leica CM1850 cryostat
(Leica Mikrosysteme GmbH, Vienna, Austria). To iden-
tify human stem cells transplanted into the rat spinal
cord, antibodies directed against human nuclei (HuNu)
(Chemicon, Temecula, CA, USA) and human mitochon-
drial marker (MTC02) (Abcam, Cambridge, UK) were
used. To follow the fate of the transplanted stem cells
and their communication with the host tissue, antibodies
directed against nestin, neurospecific enolase (NSE),
chondroitin sulfate proteoglycan (NG2), calcitonin gene-
related peptide (CGRP) (all Millipore); neurofilament
160 (NF160), neurofilament 200 (NF200), glial fibrillary
acidic protein (GFAP) (all Sigma, St. Louis, MO, USA);
Olig2, choline acetyltransferase (ChAT), 2ʹ,3ʹ-cyclic nu-
cleotide 3ʹ-phosphodiesterase (CNPase), Ki67 (all Abcam);
Islet2, Nkx6.1 (DSHB, Iowa City, IA, USA), and Tau
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visualize primary antibody reactivity, appropriate second-
ary antibodies were used: goat anti-mouse IgG conjugated
with Alexa-Fluor 488 and 594 and goat anti-rabbit IgG
conjugated with Alexa-Fluor 594 (Molecular Probes,
Eugene, OR, USA). Confocal images were taken with a
Zeiss LSM 5 Duo confocal microscope (Carl Zeiss).
To count the number of transplanted cells, every sixth
longitudinal cryostat section (14-μm thickness) of the
spinal cord was chosen for imaging the whole graft area.
Images were taken with an Observer D1 microscope
(Carl Zeiss). The surviving human cells, which were rec-
ognized as HuNu-positive cells, were counted in each
section by using ImageJ software. The total number of
cells was estimated according to the volume of the sec-
tion in which the cells were found. The percentage of
surviving transplanted cells was calculated by dividing
the estimated total number of surviving cells by the total
number of transplanted cells (5 × 105). The percentage
of transplanted cells positive for specific markers was
calculated as the ratio of Ki-67- or Nkx6.1-positive cells
to the total of surviving HuNu-positive cells.
To visualize nanoparticle internalization in rats
transplanted with magnetically labeled cells (n = 4), po-
tassium ferrocyanide (1 g of K4[Fe(CN)6]3H2O dissolved
in 100 ml 0.5% HCl) was applied for 30 minutes to pro-
duce ferric ferrocyanide [prussian blue staining for ferric
(3+) iron].
RNA extraction and quantitative PCR analysis of gene
expression
Total RNA was extracted from rat spinal cord tissue and
human fetal neural stem cells by using the RNeasy Lipid
Tissue Mini Kit (Cat. no. 74804) and RNeasy Plus Mini
Kit (Cat. no. 74134), both from Qiagen GmbH (Hilden,
Germany) according to the manufacturer’s instructions.
Spinal cord tissue was dissected from animals of three
different groups: intact healthy animals without SCI
(n = 4), animals with SCI only (n = 4), and animals
grafted with SPC-01 cells (n = 4) and killed 8 weeks after
transplantation.
The expressions of rat (Rattus norvegicus) target genes
Bdnf,Vegfa, Ngf, and Nt3 (Sort1) and human (Homo sapi-
ens) target genes BDNF, VEGFA, NGF, NT3 (SORT1),
NKX6-1, ISL2, HB9 (MNX1), SYP, and CHAT were deter-
mined by quantitative real-time reverse transcription poly-
merase chain reaction (qPCR) in a 7500 Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) by
using TaqMan Gene Expression Master Mix (catalog




1458_m1/NGF/, Hs00361760_m1/SORT1/, Hs00232355_m1/NKX6-1/, Hs00377575_m1/ISL2/, Hs00907365_
m1/MNX1/, Hs00300531_m1/SYP/, Hs00252848_m1/
CHAT). The qPCR was carried out in a final volume of 20
μl containing 500 ng of extracted RNA. The following
thermal profile was used: a single cycle of reverse tran-
scription for 30 minutes at 50°C and 15 minutes at 95°C
for reverse transcriptase inactivation and DNA polymerase
activation, followed by 40 cycles of denaturation at 95°C
for 15 seconds and annealing and extension at 60°C for 1
minute. The results were analyzed by using the integrated
7500 System SDS Software (version 1.3.1). Each data set
was normalized with an appropriate TaqMan endogenous
control selected by NormFinder [28]. As endogenous
control genes, Actb (Rn00667869_m1) and GAPDH
(Hs99999905_m1) were chosen for rat and human target
genes, respectively. All qPCR reagents were provided by
Applied Biosystems Foster City, CA, USA. Finally, the data
were recalculated to relative quantities and transformed to
a log2 scale by using the Relative Expression Software Tool
(REST) [29]. In the case of the unexpressed NGF gene in
SPC-01 cells before differentiation, the undetermined
cycle of quantification (Cq) value was set to a maximum
(for example, 40) for the calculation of the relative expres-
sion ratio. All numeric data were presented as mean ±
standard deviation and analyzed statistically by using REST.
Results
FACS analysis of SPC-01 cells
To characterize the expression of pluripotent and neural
markers in human fetal neural stem cells from the SPC-
01 line, a series of FACS analyses was performed before
transplantation (a description of the FACS analysis
method, the results, and figure S1 are presented in the
Additional files 2 and 3). The flow-cytometry results re-
vealed that SPC-01 cells display a clear neural profile in
terms of their marker expression. At the same time,
these cells are negative for pluripotent markers, which
suggests that they are safe for use in transplantation
experiments.
BBB test
The motor recovery of the hind legs after SCI was exam-
ined weekly by using the BBB test (Figure 1A). The
hindlimb function was severely damaged by the balloon
compression: BBB scores were between 0 and 2 a week
after surgery. The control animals with a balloon-
compressed thoracic spinal cord, and saline injection
showed spontaneous functional recovery as quickly as
the transplanted animals during the first 3 weeks after
lesioning. The final score of control animals on the BBB
test was 4.19 ± 0.38 at 9 weeks after SCI. In contrast, the
transplanted animals started to show a significant im-
provement of their hindlimb locomotion 4 weeks after
SCI (3 weeks after transplantation) compared with the
Figure 1 Functional recovery after SPC-01 cell transplantation. Hindlimb locomotor function was assessed weekly with the open-field BBB
test (A). A significant difference between the control and the transplanted animals was found at 4 weeks after SCI (*P < 0.05). The withdrawal
latency of the hindpaw in response to a heat stimulus was measured weekly with the Plantar test (B). A significant difference in withdrawal
latency compared with the controls appeared from 7 weeks after SCI (*P < 0.05). A statistically significant difference between the control and
transplanted groups in the scores of the flat beam walking test (C) appeared at 7 weeks after SCI (6 weeks after transplantation) (*P < 0.05). Tx
marks the day of transplantation.
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± 0.48. Extensive joint movement, which is recognized as
a flexion angle of more than half of the possible range of
motion of the joint, was observed in all joints of the hind
legs (three joints in each leg) in 65% of the transplanted
animals at the end of the experiments, but in only one
animal (6.3%) among the control group. In addition,
in transplanted animals, body weight was supported
on their hind legs, and paw stepping was seen in 15%
of them.
Plantar test
For sensitivity testing, the withdrawal latency of the
hindpaws from a thermal stimulus was examined weekly
after SCI (Figure 1B). The average latency determined
from five repeated measurements for each paw was 8.08
± 0.22 seconds in the control animals and 8.13 ± 0.20
seconds in the transplanted animals 1 week after SCI,
which decreased to 6.34 ± 0.14 and 6.26 ± 0.18 seconds,
2 weeks after SCI (1 week after transplantation), respect-
ively. The control animals did not improve their latency
further; their final average latency at 9 weeks after SCI
was 6.30 ± 0.19 seconds. In contrast, the transplanted
animals shortened their latency during each subsequent
week and started to show significant differences com-
pared with the controls at 7 weeks after SCI (P < 0.05).
Beam-walking test
The ability to traverse a beam with a flat surface was
examined weekly. Rats with SCI, injected with saline,
were not able to transverse the beam at all, because no
signs of weight support and/or stepping were observed
(Figure 1C). However, after SPC-01 treatment, the rats
started to maintain their body weight on the beam for
60 seconds, and some of them could traverse the beam.
A statistically significant difference appeared at 7 weeks
after SCI (6 weeks after transplantation) between the
control (0.2 ± 0.06) and transplanted (2.3 ± 0.33) groups
(P < 0.05).
In vivo imaging
To check the feasibility of tracking transplanted stem
cells, four animals were grafted with SPC-01 cells labeled
with PLL-SPIO nanoparticles. The cells were labeled be-
fore transplantation. The viability of the labeled cells
was 88%, and the labeling efficiency was 57%, which
means that 57% of cells were labeled. (The methods used
to evaluate cell viability and labeling efficiency are de-
scribed in Additional file 2).
The spinal cord lesion was visible on T2-weighted MR
images 5 days after lesioning as a hyperintense signal
(Figure 2A), probably representing edema. The grafted
cells were detected in the lesion on T2-weighted images
as a strong hypointense area (Figure 2B) in the cranialpart of the lesion, compared with the hyperintense signal
in the nontransplanted lesioned spinal cord (Figure 2C).
These MR images corresponded to the MTCO2- and
Prussian blue-stained tissue sections (Figure 2D, E). The
grafted SPC-01 cells were identified as a packed cell
mass. However, the Prussian blue-stained nanoparti-
cles were more accumulated inside the cell mass com-
pared with the margins of the immunostained cell
mass, indicating that some of the cells expelled the
label (Figure 2F). We speculate that the expulsion of
nanoparticles can happen because of the differenti-
ation of stem cells, particularly into astrocytes, be-
cause we already saw this in our previous experiments.
However, graft survival and the differentiation pattern
(see later) were not affected by magnetic labeling, and
we did not observe any difference between labeled and
unlabeled cells, which were detected by staining for
MTCO2 or HuNu.
Morphometric evaluation of the spared white and gray
matter
The area of the white and gray matter was calculated be-
tween 1-cm cranial and 1-cm caudal to the injury epi-
center. The cross-sectional areas (mm2) were plotted at
1-mm increments from the injury epicenter, which
was recognized as the smallest area of the spinal cord
(Figure 3A). The area of the white matter was calculated
by subtracting the areas of the gray matter and the cavity
that was created after SCI from the total area of the
spinal cord. In grafted animals, when compared with le-
sioned controls, the white matter was significantly
spared in the front segment rostral to 7-mm cranial to
the injury epicenter and in the rear segment behind 4-
mm caudal to the injury epicenter (P < 0.05). No signifi-
cant difference was noted in the extent of gray-matter
sparing (P > 0.05). This was clearly shown when the vol-
ume (mm3) of the white matter was compared in five
different parts of the spinal cord (front, 7 to 10 mm
cranial; middle front, 3 to 6 mm cranial; center, between
2 mm cranial and caudal to the injury epicenter; mid-
dle back, 3 to 6 mm caudal; back, 7 to 10 mm caudal)
(Figure 3B). No statistically significant differences were
found around the injury epicenter (P > 0.05). The sparing
of the white matter was prominent throughout the
spinal cord, apart from the injury epicenter and the
transplanted area.
In vivo cell survival and differentiation
SPC-01 cells were tested in the lesioned rat spinal cord
in terms of their survival and differentiation into neur-
onal and glial phenotypes. In total, 5 × 105 cells were im-
planted into the center of a spinal cord lesion. The
engrafted cells were identified either by GFP positivity
or by immunohistochemical staining for the human-
Figure 2 T2-weighted MR images of the injured spinal cord before and after SPC-01 cell transplantation. T2-weighted MR images of a
spinal cord lesion 5 days after lesion induction, before transplantation (A), a spinal cord with a cell graft 8 weeks after cell transplantation (B), and
a control spinal cord lesion 8 weeks after saline injection (C). Two serial sections were stained for MTC02 (D) and iron (E) and their overlay (F).
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ity of the grafted cells lost their GFP positivity 8 weeks
after transplantation, we therefore had to rely on stain-
ing for human-specific markers (Figure 4A). The animals
were killed 8 or 17 weeks after transplantation, and cell
survival was evaluated by examining serial longitudinal
sections of the lesioned spinal cord at both time points.
The results showed that the cells robustly survived in
the lesion: during the entire experiment, we found
grafts in 19 of 20 animals. Grafted cells also did not
form tumors during the entire period of observation,
and 8 weeks after transplantation, the Ki67 index was
3.24% ± 0.12%. The cells formed several “densely
packed clouds” and filled the lesioned tissue over a few
millimeters along the longitudinal axis of the spinalFigure 3 Morphometric evaluation of the spared white and gray mat
of grafted animals compared with SCI-only animals (*P < 0.05). No changes
measuring the volume (mm3) of the white matter in five different parts of
cranial; center, between 2 mm cranial and caudal to the injury epicenter; mcord (Figure 4A), creating their own microenvironment
with a few host cells. When the cells came into close
contact with the uninjured spinal cord tissue, they grew
into the host tissue: some cell bodies spread out of the
cell mass into the host tissue and extended their pro-
cesses (Figure 4A1).
Quantitative analyses of the survival of SPC-01 cells
were made from serial cross sections. The total volume
of the cell mass remaining 8 weeks after transplantation
was 0.29 mm3 ± 0.06 mm3 on average, and the percent-
age of surviving SPC-01 cells was 17.4% ± 2.7%.
Eight weeks after transplantation, grafted cells expressed
early neural markers such as NSE and nestin, the early
oligodendroglial marker Olig2, and the astroglial marker
GFAP (all data shown in Additional file 4: Figure S2).ter. The white matter (WM) was significantly spared in the spinal cord
were found in the gray matter (GM) (A). This was confirmed by
the spinal cord (front, 7 to 10 mm cranial; middle front, 3 to 6 mm
iddle back, 3 to 6 mm caudal; back, 7 to −10 mm caudal) (B).
Figure 4 The survival and trophic effect of SPC-01 cells 8 weeks after transplantation. The robust engraftment (MTCO2, green) of SPC-01
cells in a lesioned rat spinal cord was observed 8 weeks after transplantation (A). At the site of contact with the intact tissue, SPC-01 cells
migrated out of the graft (A1, higher magnification of A). The processes of only a few host cells entered the implant (A2). qPCR analysis revealed
that the level of expression of the rat genes Ngf and Nt-3 was increased in the spinal cords of both control and grafted rats compared with
healthy rats; the increase was significant only in the spinal cord tissue of animals grafted with SPC-01 cells (B) (*P < 0.05). (C) Changes in the
expression of the human genes BDNF, VEGF, NT3, and NGF in SPC-01 cells 8 weeks after transplantation into a lesioned rat spinal cord, compared
with the same cells before transplantation (**P < 0.005).
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the ingrowth of neurofilaments from the host tissue into
the “cloud” of transplanted cells (Figure 4A2).
To evaluate the effect of transplanted SPC-01 cells on
endogenous regenerative processes, we examined the
gene expression of several neurotrophic factors: Bdnf,
Vegf, Ngf, and Nt3, by using qPCR (Figure 4B). Eight
weeks after transplantation, the expression of the Bdnf,
Ngf, and Nt3 genes was increased in the spinal cords of
both control and grafted rats, compared with intact an-
imals. However, only the changes in Ngf and Nt3 gene
expression in spinal cord tissue transplanted with SPC-
01 cells were significant (P < 0.05). qPCR analysis of
the expression of the same human genes in SPC-01
cells after their transplantation into the spinal cord
revealed the upregulation of BDNF and NGF and the
downregulation of VEGF and NT3 expression com-
pared with the mRNA levels before transplantation
(that is, cells in culture; Figure 4C). However, only
the change in the expression of NGF was significant(P = 0.001). It is interesting to note that NGF was
expressed in transplanted SPC-01 cells at a high level,
although the expression of this gene was not detected
in the same cells before transplantation.
Axonal sprouting in the lesion was expressed as the
number of GAP43+ fibers (Figure 5). Staining for GAP43
was more intense in cross-sections of the spinal cord
tissue of transplanted rats (Figure 5A) than in sections
from control animals (Figure 5B). The number of
GAP43+ axonal fibers per section was significantly in-
creased in grafted animals (176.55 ± 18.26) compared
with control rats (8.41 ± 3.35) (Figure 5D). The grafted
cells were not GAP43+, indicating that all sprouting
came from endogenous host axons.
To examine the ability of SPC-01 cells to differenti-
ate toward motor neurons after transplantation into
the injured rat spinal cord, we investigated the expres-
sion of motor neuron-specific markers. Immunohisto-
chemical staining revealed that 8 weeks after
transplantation, 25.31% ± 2.15% of SPC-01 cells were
Figure 5 Axonal sprouting in the injured spinal cords of control rats and rats transplanted with SPC-01 cells. Staining for GAP43
demonstrates more-intensive sprouting in the injured spinal cord tissue of rats transplanted with SPC-01 cells (A) compared with control animals
(B). (C) Higher-magnification view of the transplant area, marked by the white line in (A). (D) Quantitative analysis of the number of GAP43-positive
fibers in the spinal cord tissue of control and transplanted animals.
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lysis did not reveal changes in the expression of
this marker compared with the levels seen in SPC-01
cells before transplantation (Figure 6B). However, a
highly significant (P < 0.005) upregulation in the ex-
pression of Islet2 and HB9 in transplanted SPC-01
cells was detected with qPCR at the same time point.
Eighteen weeks (4 months) after SCI, Islet2 expres-
sion in transplanted SPC-01 cells was also detected
immunohistochemically (Figure 6C), as well as the
expression of choline acetyltransferase (ChAT) (Figure 6D).
Orthogonal projections for Figures 6A, C, and D are
presented in Additional file 5: Figure S3. These re-
sults suggest that a certain population of SPC-01
cells is able to differentiate toward a motor neuron
phenotype after transplantation into the injured rat
spinal cord. We speculate that this population con-
sists of approximately 25% of the total number of
transplanted cells.Seventeen weeks (4 months) after grafting, transplant-
ed SPC-01 cells were less positive for GFAP (Figure 7A)
and nestin (Figure 7B) than 8 weeks after grafting, and
the expression was confined to individual fibers. How-
ever, at this time, the grafted cells were not positive
for Olig2, as was the case 8 weeks after transplant-
ation, and were positive for CNPase (Additional file 4:
Figure S2F), which suggests their differentiation toward
an oligodendroglial phenotype. Co-staining for NF200
(Figure 7C), Tau (Figure 7D), CGRP (Figure 7E), and
NG2 (Figure 7F) together with markers of human cells
(MTCO2 or HuNu), revealed that newly forming host
tissue elements are intensively incorporating into the
graft and communicating with grafted cells, because the
staining for endogenous tissue elements and the staining
for human markers did not colocalize. In the host ner-
vous tissue adjacent to the transplants, endogenous cells
positive for Olig2 (Figure 7G) and MOSP (Figure 7J)
were found.
Figure 6 Differentiation of transplanted SPC-01 cells toward a motor neuronal phenotype. The expression of motor neuron-specific
markers in SPC-01 cells at 8 and 17 weeks after transplantation. Eight weeks after transplantation, 25.31% ± 2.15% of SPC-01 cells were positive for
Nkx6.1 (A, A1, A2). At the same time, according to the results of qPCR analysis, the expression of the Nkx6.1 gene in SPC-01 cells did not change,
compared with the level of expression seen in the cells before transplantation. However, the expression of the more advanced motor neuron
genes Islet2 and HB9 in transplanted cells significantly increased (**P < 0.005) compared with that observed in SPC-01 cells before transplantation
(B). Seventeen weeks after transplantation, SPC-01 cells were positive for Islet2 (C; C1, C2, C3: higher magnification of C) and ChAT (D and
D2: higher magnification of D; D1: staining for ChAT in combination with GFP and DAPI).
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In the present study, we used clone 01 of human fetal
neural stem cells (SPC-01) derived from fetal spinal cord
as a cell source to treat SCI in adult rats. We demon-
strate that SPC-01 cells differentiated toward motor
neuronal, astroglial, and oligodendroglial phenotypes in
the injured spinal cord and promoted functional recov-
ery. Generally, the transplantation of different types of
neural stem cells often results in functional improve-
ment and to some extent in neural differentiation as well
[13-15,30]. However, SPC-01 cells possess some unique
features that make them potential candidates for future
clinical use.
Parr and colleagues [31] reported that NSCs derived
from adult spinal cord differentiated into astrocytes
(31.2%), oligodendrocytes (50.3%), and neurons (less
than 1%) after transplantation into the rat spinal cord
and that no locomotor improvement occurred [31]. The
survival of adult NSCs was very poor, less than 5%. In
our study, a single injection of half a million cells into
the spinal cord resulted in a large number of surviving
cells and facilitated host tissue regeneration 8 weeks
after transplantation. This excellent cell survival contrib-
uted to the partial restoration of locomotor function (we
used only the BBB test and the beam-walking test,because the majority of tests, such as grid walking or
rotarod, require weight support and stepping, which
were not achieved by the control animals). Morphomet-
ric measurements revealed that the white matter was
markedly spared at sites remote from the injury epicen-
ter (that is, not around the injury epicenter where the
transplants were seeded). The total volume of spared
white matter in a 21-mm-long spinal cord segment was
22% greater in the transplanted group compared with
that in the control group. A single injection of a large
number of cells enabled the extremely good survival of
the transplanted cells in the lesioned area, as confirmed
by MR images, Prussian blue staining, and staining for
the human mitochondrial marker MTCO2. The cell-
survival rate of 17% is particularly noteworthy, consider-
ing that the cell-survival rate was less than 5% in the
published work of Parr and colleagues [31]. In addition,
even the injection of a rather large volume of cells did
not result in any hyperproliferation or tumor formation.
The reason for the better survival can be either the triple
immunosuppression and/or the injection of a large cell
bolus (5 × 105/5 μl), which may help the transplanted
cells to create a more-permissive environment in the
hostile lesion, because three injections of fewer cells
(1 × 105/1 μl) resulted in worse cell survival.
Figure 7 (See legend on next page.)
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Figure 7 The incorporation of host tissue elements into the graft 17 weeks after transplantation. SPC-01 cell survival and migration 17
weeks after transplantation was similar to that seen at 8 weeks. Transplanted cells were positive for GFAP (A and A1: higher magnification of
A) and nestin (B and B1: higher magnification of B). At the same time, the grafts were infiltrated by endogenous cells and cell elements positive
for NF200 (C and C1 and C2: higher magnification of C), Tau (D and D1), CGRP (E and E1), and NG2 (F), which suggests good communication
with the host tissue. In the host nervous tissue adjacent to the transplants, endogenous cells positive for Olig2 (G) and MOSP (J) were found
surrounding the implant.
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beled before transplantation with PLL-SPIO nanoparticles.
Several studies have used magnetically labeled cells
to monitor the fate of transplanted cells within the
organism [22,32,33]. Cells labeled with iron-oxide
nanoparticles (at a similar concentration) can migrate,
differentiate, and improve functional outcome in dif-
ferent diseases [11,34]. It is possible to monitor SPIO-
labeled neural stem cells for 18 weeks after transplant-
ation [35]. The cells can differentiate into neuronal
and glial lineages and have neuronal-like electro-
physiological characteristics, with no signs of tumor
formation. Similarly, subventricular zone (SVZ) cells
labeled by ferromagnetic particles were transplant-
ed intracisternally into a rat model of stroke. The
transplanted cells selectively migrated toward the is-
chemic parenchyma, and the grafted animals exhibited
significant improvement of their neurologic function
[36]. In our experiments, we followed the animals by
using MRI only for 8 weeks. The graft was clearly vis-
ible at the cranial side of the lesion, although the
labeling efficiency was only 57%. By 8 weeks after
transplantation, the transplanted cells were mainly
nestin- and GFAP-positive, no matter whether the
cells were nanoparticle-labeled or not. Also, no differ-
ence was observed in behavioral tests between animals
that were transplanted with labeled or unlabeled cells.
However, the morphometric evaluation of the spared
white and gray matter, as well as the qPCR analyses,
were performed in animals grafted with unlabeled
cells, although it was shown that the secretion profile
of ferumoxide-labeled human bone marrow, mesen-
chymal cells was not impaired by the labeling, includ-
ing the production of growth factors and cytokines
mediating the recovery effect [37]. To study more
precisely the effect of SPIO nanoparticles on in vivo
differentiation and the dynamics of nanoparticle expul-
sion, further long-term studies would have to be
performed.
We have seen functional improvement as early as 3
weeks after transplantation. However, 5 weeks later (that
is, 8 weeks after transplantation), grafted SPC-01 cells
still expressed mainly progenitor markers, such as Olig2,
nestin, and NSE, and were GFAP positive. Conversely, at
this same time, the robust sprouting of endogenous neu-
rons, positive for GAP43, was observed, most likely dueto a paracrine effect of the graft by which the expression
of the NGF gene was significantly upregulated. More-
over, the transplantation of SPC-01 cells led to the
upregulated expression of the rat neurotrophin genes
Nt3 and Ngf compared with lesioned control animals.
Neurotrophic factors such as NGF, BDNF, and NT3 play
critical roles in axonal growth and in the survival of
existing neurons [38-41]. Consistent with these reports,
we observed that SPC-01 cell transplantation promoted
functional recovery after SCI. Therefore, we suggest that
the early significant improvement in motor and sensory
tests was mediated by the increased expression of neuro-
trophic factors by the transplanted SPC-01 cells, espe-
cially NGF. Human cells, although they are transplanted
into rodent tissue, mature much more slowly than their
mouse or rat counterparts. A similar effect was observed
in our study when NSCs derived from human iPS cells
were injected into animals with middle cerebral artery oc-
clusion (a model of stroke). Functional outcome and the
protection of the host substantia nigra from atrophy were
also observed much earlier than the slow maturation
of human GABAergic neurons and their innervation
of the host substantia nigra [42]. Here, we demonstrate
that around 25% of the transplanted SPC-01 cells were
able to differentiate toward a motor neuronal phenotype.
At 8 weeks after transplantation, increased expression
levels of motor neuron-specific markers were detected
with qPCR; however, only the early motor neuron marker
Nkx6.1 was detected immunohistochemically. Neverthe-
less, 2 months is too short a period for the terminal differ-
entiation and maturation of human cells in vivo. It was 2
months later (week 17) when we were able to detect
immunohistochemically Islet2 and ChAT, markers of
postmitotic motor neurons, in grafted SPC-01 cells. We
did not study the incorporation and communication of
newly formed motor neurons with the host tissue. This as-
pect of the stem cell therapy effect on recovery after SCI
remains as a task for future experiments.
Neuronal differentiation does not equal neural tissue
reconstruction. However, during our experiments, we
observed the progressive ingrowth of host axons into
the implant. Seven weeks after grafting, the SPC-01
cells formed dense clouds, and only sparse host
neurofilaments were detected growing into the graft.
Two months later, the graft was robustly grown
through with neurofilaments, and we found host axons
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tion, we observed clusters of NG2- Olig2-, and MOSP-
positive cells surrounding the SPC-01 implants. It was
shown that oligodendrocytes possess neurotrophin re-
ceptors [43], and we can speculate that host oligoden-
drocytes and their progenitors are attracted by the
elevated concentration of neurotrophic growth factors
in the graft.
Conclusions
The SPC-01 cell line can be expanded in large quan-
tities and, when implanted into an animal model of
SCI, the cells robustly survive in the lesion, express
neurotrophins, stimulate the expression of host neuro-
trophic genes, and facilitate the sprouting of endogen-
ous GAP43-positive axons. All of these actions lead to
improvements in locomotor and sensory functions and
to the sparing of the white matter in the short term. In
the long term, about 25% of transplanted SPC-01 cells
can slowly mature into motor neurons and participate
to some extent in tissue reconstruction. SPC-01 cells
were derived by using the same protocol as the
CTX0E03 immortalized cell line derived from human
cortical neuroepithelium [18]. These cells are currently
undergoing testing in a human clinical trial for stroke
patients. Similarly, our results represent a proof-of-con-
cept that conditionally immortalized neural stem cell
lines from human spinal cord could be used in the fu-
ture for cell therapy in SCI patients.
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